»ùÓÚÃâÒß×éÖ¯»¯Ñ§£¨IHC£©ºÍÔλÔÓ½»£¨ISH£©Ð§¹û£¬·ºÆðÁËÒ»ÖÖHER2µÍ±í´ïµÄÈéÏÙ°©£¨BC£©ÑÇÐÍ£¬ÆäÊýĿռËùÓÐBCµÄÒ»°ëÒÔÉÏ¡£Èç×îÐÂÖ¸ÄÏËùÇ¿µ÷µÄÄÇÑù£¬ÈËÃÇÔ½À´Ô½ÖØÊÓBCÖÐHER2µÄµÍ±í´ïÕ÷Ï󣬲¢½«Æä½ç˵ΪIHC1+»òIHC2+/ISH-£¨HER2/CEP17±ÈÖµ<2.0£©¡£
È»¶ø£¬ÎÒÃǹØÓÚHER2-lowÈéÏÙ°©µÄʶ±ð¿ÉÄܱ£´æ²»Í¬¡£×î½ü£¬Óб¨µÀչʾÁ˲¡Àíѧ¼ÒÃÇʹÓÃÃâÒß×黯¶Ô HER2 ¾ÙÐÐÆÀ·ÖµÄ¶à»ú¹¹ÆÀ¹ÀЧ¹û£ºÊ¹ÓÃ4ÀàHER2 IHCÆÀ·ÖϵͳÊӲ쵽µÄÖÐÐÄÖÖ±ð£¨IHC1+ºÍIHC2+£©±£´æÊµÖÊÐÔ²î±ð£¬Ò»ÖÂÐÔ»®·ÖСÓÚ1%ºÍ3.6%¡£Í¬Ê±£¬ÔÚIHC ÆÀ·ÖΪ0µÄÑù±¾Öвî±ðÒ²ºÜ´ó£¬×ÜÌåÒ»ÖÂÐÔ½öΪ25%¡£ÒòÅбðHER2 IHCÆÀ·Ö0ºÍ1+Ö±µ½×î½ü²Å¾ßÓÐÁÙ´²ÒâÒ壬¶øÈ·ÈÏHER2 IHC 0 µ½ 1+ Ö®¼äµÄãÐÖµÊÜÈËΪÒòËØµÄÓ°Ï죬¿ÉÄܻᵼÖ¶ÔÇкÏHER2µÍ±í´ï°ÐÏòÖÎÁÆÌõ¼þµÄ»¼ÕßµÄʶ±ðЧ¹û²»¼Ñ¡£
±¾Ñо¿ÊǶÔHER2µÍ±í´ïÖ×ÁöÍŽáNGS±íÕ÷µÄ¿´·¨ÑéÖ¤¡¢»ØÊ×ÐÔÑо¿£¬Ê¹ÓÃNGSÆÀ¹ÀÒѽÓÊÜͨÀý IHC ER¡¢PR¡¢Ki67 ºÍHER2 ±í´ï¼ì²âÈéÏÙ°©Ñù±¾µÄERBB2»ùÒòÀ©Ôö¡£Í¬Ê±ÖØµã¹Ø×¢ÁËNGSÆÊÎöµÄЧÁ¦£¬Ê¶±ðÆäËû¾ßÓÐÁÙ´²ÒâÒåµÄ·Ö×Ӱб꣬°üÀ¨ESR1¡¢PIK3CA¡¢AKT1¡¢ERBB2¡¢TP53¡¢BRCA1ºÍBRCA2¡¢CNVÒÔ¼°MSI¡£
±³ ¾°
ºÍ¼¤ËØÊÜÌ壨HR£©¡¢´Æ¼¤ËØ£¨ER£©ºÍÔм¤ËØÊÜÌ壨PR£©±í´ïÒ»Ñù£¬HER2±í´ï״̬ҲÊÇÈéÏÙ°©£¨BC£©Õï¶ÏµÄ±ê×¼¡£µ±Ê¹ÓÃÃâÒß×黯£¨IHC£©¾ÙÐÐÆÀ¹Àʱ£¬Æ¾Ö¤È¾É«Ç¿¶È¡¢HER2ÑôÐÔÖ×Áöϸ°ûµÄ°Ù·Ö±È£¬ÒÔ0ÖÁ3+µÄÆ·¼¶¶ÔERBB2»ùÒò±àÂëµÄHER2ÂѰ׵ıí´ï¾ÙÐÐÆÀ·Ö¡£ÔÚHER2 2+µÄÇéÐÎÏ£¬Ê¹ÓÃÔλÔÓ½»£¨ISH£©¼ì²âHER2»ùÒòµÄÀ©Ôö¡£×÷Ϊ²Î¿¼£¬¾ÙÐÐ17ºÅȾɫÌå×ÅË¿Á££¨CEP17£©µÄ±ê¼Ç£¬µ±¼ì²âµ½¸ßˮƽµÄ»ùÒòÀ©Ôö£¨ERBB2/CEP17 ±ÈÖµ > 2.0£©Ê±£¬½ç˵Ö×ÁöΪISHÑôÐÔ¡£
ÈçÏÂͼËùʾ£¬HER2ÑôÐÔ״̬½ç˵Ϊǿ£¨3+£©IHC¹ý±í´ï»òÖеȣ¨2+£©IHC¹ý±í´ïͬʱ»ùÒòÀ©Ôö£¨ISH+£©¡£10%-20%µÄBCΪHER2ÑôÐÔ£¬HER2ÑôÐÔBC»¼Õ߿ɽÓÊÜÕë¶ÔHER2ÂѰ׵İÐÏòÖÎÁÆ£¬Èçµ¥¿Ë¡¿¹ÌåÇúÍ×Öéµ¥¿¹ºÍÅÁÍ×Öéµ¥¿¹¡¢¼¤Ã¸ÒÖÖÆ¼ÁÀÅÁÌæÄᣬÒÔ¼°¿¹Ìå-Ò©ÎïżÁªÎï £¨ADC£©µÂÇúÍ×Öéµ¥¿¹¡£
ÒªÁìѧ
´ÓÂåÁÖ°©Ö¢Ñо¿ËùµÄ»ú¹¹Ö×Áö¿âÖÐÈë×éÁË31¸öFFPE BCÖ×Áö±ê±¾£»½«Ö×ÁöÀο¿ÔÚ 4% »º³å¼×ȩˮÈÜÒºÖÐÖÁÉÙ 12 Сʱ£¨»î¼ì£©»ò24Сʱ£¨ÊÖÊõ±ê±¾£©£¬È»ºó°üÂñʯÀ¯¡£½ÓÄÉÃâÒß×黯·¨¼ì²âCK19¡¢´Æ¼¤ËØÊÜÌ壨ER£©¡¢Ôм¤ËØÊÜÌ壨PR£©¡¢HER2ºÍKi-67µÄ±í´ï¡£
ʹÓö¨ÖÆÉè¼ÆµÄ¡¢»ùÓÚ²¶»ñµÄ“¹ÌÌåÖ×ÁöÈÜÒº”ÊÔ¼ÁºÐ£¨Sophia Genetics£¬Geneva£¬Switzerland£©´Ó100ngÌáÈ¡µÄÖ×ÁöDNAÖÆ±¸NGSÎĿ⣬¸ÃÊÔ¼ÁºÐº¸ÇÁË51¸ö°©Ö¢Ïà¹Ø»ùÒòµÄÁÙ´²¹Ø×¢ÇøÓò£¬ÆäÖаüÀ¨BC·Ö×ӰлùÒò£¬ÈçESR1¡¢PIK3CA¡¢AKT1¡¢ERBB2¡¢TP53¡¢BRCA1ºÍBRCA2¡£Ê¹ÓÃMiSeq²âÐòÒÇ£¨Illumina£©¾ÙÐаÐÏò²âÐò¡£
½á ÂÛ
ÔÚÒ»ÏßIHCͨÀýÆÊÎöÖ®ºó£¬NGS¿ÉÒÔÌṩ¶à¸öÉúÎï±ê¼ÇÎïÐÅÏ¢¼°MSI״̬£¬´Ó¶øÊ¹HER2-lowºÍTNBC»¼Õß»ñÒæ£¬²¢Í¬Ê±½ÚÔ¼ÁËÑùʵÖÊÁϺÍʱ¼ä¡£
Ч¹û 1£ºKi67±í´ïÔÚHer2+µÄÈéÏÙ°©Ñù±¾ÖÐÏÔÖøÉý¸ß£¬NGSÓëFishЧ¹û¾ßÓÐÒ»ÖÂÐÔ¡£
´ó´ó¶¼Ö×ÁöΪ¼¤ËØÊÜÌåÑôÐÔ£¨29/31£©£¬½ç˵Ϊ ER£¨23/31£©»ò PR£¨23/31£©±í´ïÑôÐÔ¡£ËùÓÐÖ×ÁöµÄER/PR±í´ï¾ù¸ßÓÚ10%¡£
HER2 IHCЧ¹ûÏÔʾ£¬ËùÓÐ31ÀýÑù±¾ÖУ¬10ÀýIHC 0¡¢5Àý IHC1+¡¢9Àý IHC2+ºÍ7Àý IHC3+¡£Ê¹ÓÃISH½øÒ»²½ÆÊÎö9¸öHER2 IHC2+Ö×Áö£¬ÔÚ4/9Ö×ÁöÖÐÊӲ쵽HER2À©Ôö£¨44%£©¡£ËùÓÐÆÊÎöµÄBCÈËȺ°üÀ¨10¸öHER2ÒõÐÔ¡¢10¸öHER2µÍ±í´ïºÍ 11 ¸ö HER2 ÑôÐÔÖ×Áö¡£
KI67±ê¼Ç¹æÄ£Îª2-80%£¬ÈéÏÙ°©KI67±ê¼ÇÔÚHER2+£¨IHC3+»òIHC2+ºÍISH+£©ÖÐÏÔÖø¸ßÓÚHER2ÒõÐÔ£¨IHC0£©ºÍHER2µÍ±í´ï£¨IHC1+»ò IHC2+¡¢ISH-£©£¬Æ½¾ùֵΪ 34.2£¨SD = 19.2£©¡¢15.8£¨SD = 13.4£©ºÍ13.5£¨SD = 6.5£©£¨ÈçÏÂͼA£©¡£
µ±Ê¹ÓÃNGS¼ì²â£¬HER2ÑôÐÔ¡¢HER2µÍ±í´ï¡¢HER2ÒõÐÔÖ×ÁöÖ®¼äµÄERBB2»ùÒòµÄCNVÖµÓÐÏÔÖø²î±ð£¨p < 0.001£©£¬Æ½¾ùÖµ»®·ÖΪ7.8£¨SD = 6.8£©¡¢1.9£¨SD = 0.3£©ºÍ2.0£¨SD = 0.3£©£¨ÈçÏÂͼ2B£©¡£µ± CNV µÄÁÙ½çÖµÉèÖÃΪ 3.25 ʱ£¬³ýÒ»¸öÑùÆ·£¨ÑùÆ· #24£©Í⣬ËùÓÐÑùÆ·µÄ ISH ºÍ NGS Ö®¼äµÄ HER2 À©Ôö״̬һÖ¡£×ÜÖ®£¬IHCÍŽáNGS ÓëIHC ÍŽá ISHµÄЧ¹ûÒ»ÖÂÐÔΪ96.8%¡£
Ч¹û 2£ºNGS½øÒ»²½¼ì²â³öÓÐÁÙ´²ÒâÒåµÄλµã¡£
ÔÚ19%£¨6/31£©µÄ²¡ÀýÖУ¬HER2ÒõÐÔÖ×Áö£¨2ÀýFGFR1À©Ôö£¬2ÀýMYOD1À©Ôö£©ºÍHER2ÑôÐÔÖ×Áö£¨1ÀýFGFR1À©Ôö£¬1ÀýPIK3CAÀ©Ôö£¬1ÀýROS1À©Ôö£©Í¬Ê±¼ì²âµ½ÌØÁíÍâ»ùÒòÀ©Ôö¡£
ÔÚ68%£¨21/31£©µÄ²¡ÀýÖУ¬ÓÐ12¸öPIK3CA¡¢6¸öTP53¡¢2¸öAKT1ºÍ4¸öBRCA2Í»±ä£¬ÔÚ51¸ö»ùÒò×éºÏÖмì²âµ½ÆäËûÖ²¡ÐԺͿÉÄܵÄÖ²¡»ùÒòÍ»±ä¡£
±ðµÄ£¬ÔÚЯ´øPIK3CA»ùÒòÍ»±äµÄHER2ÒõÐÔ¡¢ISHδÀ©Ôö¡¢HRÑôÐÔÖ×ÁöÖмì²âµ½Ò»ÀýMSI ״̬£¨c.1624G > A£¬p.£¨Glu542Lys£©£©¡£
ÌÖ ÂÛ
HER2µÍ±í´ïBCÕ¼HR+Ö×ÁöµÄ40%-65%£¬23-40%µÄHRÒõÐÔÖ×Áö±í´ïµÍˮƽHER2¡£HER2µÄ±í´ïÊǶ¯Ì¬µÄ£¬²¢ÇÒÔ·¢Ö×ÁöºÍÍíÆÚ¼²²¡Ö®¼äµÄת»¯ÂÊ·×ÆçÖ¡£ÕâЩЧ¹ûÇ¿µ÷£¬ÔÚ¼²²¡Ï£Íûʱ¾ÙÐÐÖØ¸´Éú¼ìÊÇÓÐÓõģ¬Õâ¿ÉÄÜ»áÓ°ÏìÖÎÁÆÑ¡Ôñ¡£Æ¾Ö¤¼¤ËØÊÜÌå £¨HR£© ºÍ HER2 µÄ±í´ï£¬BCÒ»¾±»·ÖÀà·ÖΪËÄÖÖÑÇÐÍ£º¹ÜÇ» A£¨HR+ºÍ HER2-£©¡¢¹ÜÇ»B£¨HR+ºÍ HER2+£©¡¢HER2ÑôÐÔ£¨HR−ºÍHER2+£©ºÍÈýÒõÐÔBC£¨TNBC¡¢HR-ºÍHER2-£©£¬ÆäÖÐTNBCͨ³£±»ÒÔΪÊÇÔ¤ºó×î²îµÄ¡£HER2-low BCÊÇHER2ÒõÐÔÖеÄÒ»ÖÖÒìÖÊÐÔ¼²²¡£¬ÌåÏÖ³öDESTINY-Breast04 ÈýÆÚÊÔÑéÕ¹ÏÖÁËT-DXdÔÚ¼ÈÍù½ÓÊܹýÒ»Ïß»ò¶þÏß»¯ÁƵÄ×ªÒÆÐÔÈéÏÙ°©»¼ÕßHER2-lowÖеÄÁÆÐ§£¬ÓëÒ½ÉúÑ¡ÔñµÄ»¯ÁÆÏà±È£¬T-DXdÏÔÖøÔöÌíÁËPFSºÍOS¡£¶øÔÚDAISYÊÔÑéÖУ¬×ÝÈ»HER2±í´ïˮƽºÜÊǵͣ¬ËƺõÒ²ÄÜÇý¶¯T-DXdµÄϸ°ûÉãÈ¡»òÆäËû×ÔÁ¦ÓÚHER2µÄ»úÖÆ£¬²¿·Ö¼ÓÈëÁËT-DXdµÄÁÆÐ§¡£
Òò´Ë£¬Ê¶±ðHER2µÍ±í´ï״̬ÔÚBCµÄ¹ÜÀíÖбäµÃÖÁ¹ØÖ÷Òª£¬µ«¼ì²âÒªÁìѧ¿ÉÄÜ»áÓ°Ïì HER2¡¢IHC ºÍ ISH ͨÀý¼ì²âµÄÃô¸ÐÐԺͿÉÖØ¸´ÐÔ£»Í¬Ê±Ó¦Ë¼Á¿HER2±í´ï»òÀ©ÔöµÄÒìÖÊÐÔ£¬ÒÔ¸ÄÉÆHER2µÍ±í´ïµÄʶ±ð¡£NGSÊÖÒÕµÄÉú³¤ÎªÈéÏÙ°©£¨BC£©ºÍÈýÒõÐÔÈéÏÙ°©µÄ¾«×¼Ò½ÁÆÖÎÁÆÕ½ÂÔ´øÀ´ÁËÏ£Íû¡£×î½üÔÚ¹ú¼ÊÖ¸ÄÏÖÐÔöÌíµÄÐ޸İüÀ¨ESR1»ùÒòÍ»±äºÍÄÇЩÈÔÐèÒªÑéÖ¤ÐÔǰհÐÔÑо¿µÄÍ»±ä£¬µ«ÁÆÐ§Ö¤¾Ý¿ÉÓ㬰üÀ¨ PIK3CA¡¢AKT1¡¢HER2¡¢TP53¡¢BRCA1 ¡£PIK3CAÍ»±äºÍÀ©ÔöԼα£´æÓÚ10%µÄHRÑôÐÔºÍHER2ÒõÐÔµÄÔ·¢ÐÔBC»¼ÕßÖУ¬ÆäÀ©Ôö»¼ÕßµÄϳ¡½Ï²î¡£³ýÁËÍ»±äÖ®Í⣬»ùÒòÀ©ÔöµÄÅжÏÒ²Ô½À´Ô½Êܵ½¹Ø×¢¡£±¾Ñо¿Öз¢Ã÷µÄһЩÀ©Ôö¾ÍÊÇÕâÖÖÇéÐΡ£×îºó£¬MSI ״̬¿ÉÒÔ×÷ΪÉúÎï±ê¼ÇÎ¼È±£´æÓÚTNBC£¬Ò²¼ûÓÚHER2ÒõÐÔHRÑôÐÔµÄ×ªÒÆÐÔÈéÏÙ°©»¼ÕßÖС£ÔÚÕâÖÖÇéÐÎÏ£¬Ê¹ÓÃNGSͬʱ²â¶¨¹ØÓÚÃâÒßÖÎÁƺÜÓмÛÖµ¡£
²Î¿¼ÎÄÏ×
Merlin JL, Husson M, Sahki N, Gilson P, Massard V, Harlé A, Leroux A. Integrated Molecular Characterization of HER2-Low Breast Cancer Using Next Generation Sequencing (NGS). Biomedicines. 2023 Nov 28;11(12):3164. doi: 10.3390/biomedicines11123164. PMID: 38137385; PMCID: PMC10740754.